MTNB - Matinas BioPharma Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.9000
-0.0012 (-0.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.9012
Open0.9233
Bid0.8800 x 1000
Ask0.9089 x 900
Day's Range0.8733 - 0.9233
52 Week Range0.4900 - 2.4900
Volume1,013,545
Avg. Volume1,948,698
Market Cap177.738M
Beta (5Y Monthly)2.82
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
All
News
Press Releases
  • GlobeNewswire

    Matinas BioPharma to Present at the Jefferies Virtual Healthcare Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview during the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:00 a.m. ET. Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator. A live webcast of the panel discussion will be available on the IR Calendar page of the Investors  section of the Company’s website (www.matinasbiopharma.com).

  • GlobeNewswire

    Matinas BioPharma Reports First Quarter 2020 Financial Results and Operational Highlights

    – ENHANCE-IT study of MAT9001 against Vascepa® set to resume in June 2020 – – EnACT study of MAT2203 in cryptococcal meningitis expected to resume in June 2020 – – Management.

  • GlobeNewswire

    Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2020 Financial and Operational Results on May 11, 2020

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, May 11, 2020 at 4:30 p.m. ET to discuss operational and financial results for the first quarter ended March 31, 2020. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.

  • GlobeNewswire

    Matinas BioPharma to Participate in Panel Discussion During Maxim Group Infectious Disease Virtual Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a panel discussion, as well as host investor meetings, during the Maxim Group Infectious Disease Virtual Conference. Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator, Soraya Dorce (sdorce@maximgrp.com). A live audio webcast of the panel discussion will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com) and at M-Vest.

  • GlobeNewswire

    Matinas BioPharma Provides Comment on Impact of Vascepa® Patent Litigation on MAT9001 and Update on COVID-19 Pandemic’s Effect on Business Operations and Clinical Programs

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United States District Court decision to invalidate patents related to Amarin Corporation’s Vascepa and also provided an update on the effect of the rapidly evolving COVID-19 pandemic on its business operations and clinical development programs. Matinas is aware of the United States District Court for the District of Nevada’s ruling yesterday in favor of the generic companies in Amarin Corporation’s patent litigation against two filers of abbreviated new drug applications, or ANDAs, for Amarin’s Vascepa.

  • GlobeNewswire

    Matinas BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

    Initiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020 Initiated efficacy phase of NIH-funded EnACT study of MAT2203 in cryptococcal meningitis.

  • ACCESSWIRE

    Matinas Biopharma Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 9, 2020 / Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March ...

  • GlobeNewswire

    Matinas BioPharma Announces Initiation of ENHANCE-IT Study of MAT9001 Against Vascepa®

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has initiated the ENHANCE-IT Study (Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia), a head-to-head pharmacodynamic (PD) study of MAT9001 against Vascepa® in patients with elevated triglycerides (150-499 mg/dL). The ENHANCE-IT study will assess MAT9001’s effectiveness in reducing triglyceride levels and other important lipid markers, as well as gather important data on bioavailability and blood levels of eicosapentaenoic acid (EPA) and other omega-3 fatty acids. “The ENHANCE-IT study is a significant next step in our clinical development program designed to highlight the impressive efficacy of MAT9001 and further distinguish its superior profile from Vascepa,” commented James J. Ferguson, M.D., Chief Medical Officer of Matinas.

  • GlobeNewswire

    Matinas BioPharma Appoints James A. Underberg, M.D. to its MAT9001 Scientific Advisory Board

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) today announced the appointment of James A. Underberg, M.D., M.S., FACPM, FACP, FNYAM, FASPC, FNLA to its Scientific Advisory Board (SAB). Dr. Underberg is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease.

  • GlobeNewswire

    Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Operational and Financial Results on March 9, 2020

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, March 9, 2020 at 8:00 a.m. ET to discuss operational and financial results for the fourth quarter and full year ended December 31, 2019. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.

  • GlobeNewswire

    Matinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that the independent Data Safety Monitoring Board (DSMB) for the EnACT study has completed its planned review of initial safety and tolerability data from the Part 1 dose escalation phase and unanimously approved proceeding with enrollment in the Part 2 efficacy phase at 2g of MAT2203 daily, the highest dose tested in Part 1. The 2g dose will be tested in the 2-week induction phase of treatment. Part 2 of the EnACT study will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals.

  • GlobeNewswire

    Matinas BioPharma Announces Closing of Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the closing  of its underwritten registered public offering of 32,260,000 shares of its common stock, offered at a price to the public of $1.55 per share for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Matinas BioPharma has granted the underwriters a 30-day option to purchase up to an additional 4,839,000 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Matinas BioPharma.

  • GlobeNewswire

    Matinas BioPharma Announces Pricing of Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 32,260,000 shares of its common stock, offered at a price to the public of $1.55 per share for expected gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Matinas BioPharma has granted the underwriters a 30-day option to purchase up to an additional 4,839,000 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Matinas BioPharma.

  • GlobeNewswire

    Matinas BioPharma Announces Proposed Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, Matinas BioPharma intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

  • GlobeNewswire

    Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has entered into a feasibility evaluation with Genentech, a member of the Roche Group. This feasibility evaluation will involve the development of oral formulations using Matinas’ lipid nano-crystal (LNC) platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. The interest shown by these companies in applying our platform delivery technology to their compounds is indicative of the emerging importance of drug delivery in the advancement of medicine.

  • GlobeNewswire

    Matinas BioPharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview, as well as host investor meetings, at the 31st Annual Piper Jaffray Healthcare Conference. Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator. A live audio webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com).

  • GlobeNewswire

    Matinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Initiated pre-screening of patients for Phase 2 ENHANCE-IT study of MAT9001 against Vascepa®. Enrollment to commence Q1 2020, with topline data expected H2 2020 – – NIH-funded.

  • GlobeNewswire

    Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2019 Operational and Financial Results on November 13, 2019

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live webcast on Wednesday, November 13, 2019 at 8:00 a.m. ET to discuss operational and financial results for the quarter ended September 30, 2019, as well as provide a corporate update. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class.

  • GlobeNewswire

    Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals. “We are extremely pleased to advance clinical development of MAT2203 for the treatment of cryptococcal meningitis,” commented Theresa Matkovits, Ph.D., Chief Development Officer of Matinas. “Antifungal resistance poses a major threat to the lives of vulnerable immunocompromised patients, and MAT2203 could provide an invaluable oral and safe treatment for severe fungal infections in these patients.

  • GlobeNewswire

    Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MAT2203, Matinas’ proprietary oral amphotericin B product, for the treatment of cryptococcosis, a life-threatening fungal infection most commonly observed in immunocompromised individuals. MAT2203 is Matinas’ orally-administered formulation of the broad-spectrum fungicidal medication amphotericin B, which is currently in Phase 2 clinical development.

  • GlobeNewswire

    Matinas BioPharma to Present at the 2019 Cantor Global Healthcare Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings, at the 2019 Cantor Global Healthcare Conference. Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator. A live audio webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com).

  • GlobeNewswire

    Matinas BioPharma Announces Pre-Screening of Patients to Determine Eligibility for Phase 2 ENHANCE-IT Study Against Vascepa®

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has commenced pre-screening patients to determine eligibility for ENHANCE-IT, its Phase 2 head-to-head pharmacodynamic (PD) study of MAT9001 against Vascepa in patients with elevated triglycerides (150-499 mg/dL). “Our second head-to-head trial against Vascepa is an important milestone for our Company, and pre-screening patients for eligibility will facilitate rapid enrollment in the first quarter of 2020,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas. The “ENHANCE-IT trial (Pharmacodynamic effects of a free fatty acid formulation of omega-3 pentaenoic acids to enhance efficacy in adults with elevated triglycerides) will be led by Kevin C. Maki, Ph.D., President and Chief Scientist of Midwest Biomedical Research, and is expected to involve approximately six sites in the United States.

  • GlobeNewswire

    Matinas BioPharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings, at the H.C. Wainwright 21st Annual Global Investment Conference. Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator. A live audio webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com).

  • GlobeNewswire

    Matinas BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    – MAT9001 program progressing ahead of schedule – – Additional head to head data vs. Vascepa® expected in 2020 – – NIH-funded Phase 1/2 EnACT trial of MAT2203.

  • GlobeNewswire

    Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2019 Operational and Financial Results on August 13, 2019

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live webcast on Tuesday, August 13, 2019 at 8:00 a.m. ET to discuss operational and financial results for the quarter ended June 30, 2019, as well as provide a corporate update. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants.